Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia

Figures & data

Table 1 General Information

	Cases	Male	Female
Case n (%)	323	132 (40.87%)	191 (59.13%)
Age median (P25, P75)	52 (34, 61)	46 (32, 61)	53 (34, 61)
Moderate n (%)	50 (15.48%)	21 (42.00%)	29 (58.00%)
Mild n (%)	273 (84.52%)	111 (40.66%)	162 (59.34%)
Smoking n (%)	28 (8.67%)	24 (85.71%)	4 (14.29%)
No smoking n (%)	293 (90.71%)	106 (36.18%)	187 (63.82%)
Previous smoking^a n (%)	2 (0.62%)	2 (0.62%)	0 (0.00%)

Notes: ^aPrevious smoking refers to having smoked once but has not been smoking for more than 1 year.

Table 2 Test Indicators

Parameters (Normal Range)	Results Median (P25, P75)
WBC (3.5–9.7×10~9/L)	7.79 (5.98, 10.00)
NEUT (1.9–7.2×10~9/L)	5.00 (3.50, 6.90)
NEUT% (43.2–71.5%)	63.70 (57.30, 71.35)
LYMPH (1.1–2.7×10~9/L)	1.80 (1.40, 2.20)
LYMPH% (16.8–43.4%)	22.40 (17.40, 29.60)
HGB (110–150g/L)	139.00 (128.50, 150.00)
PLT (135–350×10~9/L)	239.00 (193.00, 297.00)
CRP (0–8mg/L)	26.00 (5.56, 46.93)
CRB-65 Scores	0 (273, 84.52%) 1 (50, 15.48%)

Abbreviations: WBC, white blood cell; NEUT, neutrophil; NEUT%, neutrophil percentage; LYMPH, lymphocyte; LYMPH%, lymphocyte percentage; HGB, hemoglobin; PLT, platelet; CRP, C-reactive protein.

Table 3 Treatment Effect

Treatment Effect	Result
Average days of administration (days)	8.24±3.73
Improvement rate after 3 days of treatment n (%)	198 (61.3%)
Cured or improved n (%)	317 (98.14%)
Occurrence of adverse reactions n (%)	6 (1.86%)
Drug satisfaction n (%)	302 (93.50%)